leadf
logo-loader
viewBiocept Inc

Biocept's mutation-detecting Target Selector kits get nod from EU regulators

The kits are able to detect key oncogene mutations by analyzing tissue taken through surgical biopsies and circulating tumor DNA gained from blood-based liquid biopsies.

Gloved hand holding test tube of blood
Mutations in what’s known as the EGFR pathway are frequent biomarkers for lung cancer, and identifying them can help guide treatment decisions

Biocept Inc (NASDAQ:BIOC), a commercial developer of liquid biopsy tests, announced Tuesday that its Target Selector molecular assay EGFR kit has earned a CE-IVD (in-vitro diagnostic) mark from European regulators. 

The designation allows Biocept to sell its kits throughout the European Union and other CE mark geographies. The kits are able to detect key oncogene mutations by analyzing tissue taken through surgical biopsies and circulating tumor DNA (ctDNA) gained from blood-based liquid biopsies.

Mutations in what’s known as the EGFR pathway are frequent biomarkers for lung cancer, and identifying them can help guide treatment decisions, the company said. 

READ: Biocept expanding uses for its Target Selector liquid biopsy technology to detect cancer biomarkers

"Obtaining the CE-IVD Mark expands the market opportunity for our Target Selector molecular assay kits in the EU and other major international markets where we are seeing an acceleration in adoption of liquid biopsy-based testing," Biocept CEO Michael Nall said in a statement.

"We believe our Target Selector molecular assay kits offer features that uniquely meet the needs of the EU and other international markets through the highly sensitive detection of key actional mutations and while being extremely cost effective.”

The Target Selector ctDNA platform also relies on Biocept’s patented Switch-Blocker technology, which enriches specimens for mutations of interest, resulting in ultra-high sensitivity and specificity compared to other methods, the company noted. The technology is patent protected in the US, seven European countries and five international territories. 

In November, the company’s CEE-Sure Blood Collection Tube and CEE-Sure Sample Collection Shipping Kits also became available in Europe.

"Previously we announced CEE-IVD mark for our CEE-Sure ambient temperature blood collection tube and ship kit,” Nall said. “We are excited to now offer laboratories in the EU and other international markets a complete solution from sample acquisition to shipping and on through molecular assay reporting for tissue or liquid biopsy-based testing.” 

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Biocept Inc

Price: 4.86 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $65.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read